| RRC ID |
86023
|
| Author |
Kato-Shinomiya M, Sugino H, Wang L, Saito Y, He J, Tanei ZI, Oda Y, Tanikawa S, Tanino M, Gong JP, Tsuda M, Tanaka S.
|
| Title |
SLC13A5 plays an essential role in the energy shift to oxidative phosphorylation in cisplatin-resistant mesothelioma stem cells.
|
| Journal |
Pathol Int
|
| Abstract |
Mesothelioma is a highly aggressive tumor affecting an increasing number of patients worldwide. Owing to the poor clinical outcomes associated with current therapies, the development of novel therapies that target cancer stem cells (CSCs) is desirable. Here, we examined the applicability of our previously established hydrogel-based rapid CSC generation method to human mesothelioma cell lines and further analyzed the characteristics of the induced mesothelioma stem cell (MesoSC) -like cells. Human mesothelioma cell lines cultured on hydrogels presented increased expression of pan-stem cell markers and acquired spheroid formation and early tumorigenicity, suggesting that MesoSC-like cells are highly malignant. Microarray analysis demonstrated that the expression of SLC13A5, a citrate transporter involved in TCA cycle, was significantly induced in the resulting MesoSC-like cells. The overexpression of SLC13A5 resulted in a metabolic shift toward oxidative phosphorylation, increased phosphorylation of ERK and YAP, and increased SOX2 expression, leading to increased cisplatin resistance. scRNA-seq database analysis revealed that clinical mesothelioma samples contained a small number of SLC13A5-expressing cells. Our findings suggest that the hydrogel-based CSC generation method is also effective for human mesothelioma cells and that SLC13A5 may contribute to MesoSC survival. The new properties of MesoSCs revealed in this study may provide clues for establishing future treatments.
|
| Volume |
75(3)
|
| Pages |
151-165
|
| Published |
2025-3-1
|
| DOI |
10.1111/pin.70001
|
| PMID |
39912507
|
| MeSH |
Antineoplastic Agents / pharmacology
Cell Line, Tumor
Cisplatin* / pharmacology
Drug Resistance, Neoplasm*
Humans
Mesothelioma* / drug therapy
Mesothelioma* / metabolism
Mesothelioma* / pathology
Mesothelioma, Malignant
Neoplastic Stem Cells* / drug effects
Neoplastic Stem Cells* / metabolism
Neoplastic Stem Cells* / pathology
Oxidative Phosphorylation* / drug effects
Symporters* / genetics
Symporters* / metabolism
|
| IF |
2.11
|
| Resource |
| Human and Animal Cells |
ACC-MESO-4(RCB2293)
293T(RCB2202) |
